

Patients / Materials and Methods: This is an analytical, observational, cross-sectional study conducted with liver transplant patients between 2004 and 2023 at Hospital Clínico Universidad de Chile. Participants were required to complete two self-administered questionnaires: the "Simplified Medication Adherence Questionnaire" (SMAQ) to assess adherence (classified as adherent or non-adherent) and the "European Quality of Life-5 Dimensions" (EQ-5D) to assess quality of life. Additionally, a form was used to collect sociodemographic and clinical data, supplemented with information from the hospital's medical records. All data were recorded using the REDCap® platform.

Results and Discussion: The study included 29 patients with a median post-transplant follow-up of 37 months (range: 1 – 237 months). Of these patients, 41% (12 patients) were identified as non-adherent to immunosuppressive therapy, with occasional forgetfulness being the primary cause. Analysis revealed that younger patients, those with less comorbidity, and those with a longer time since transplantation were less adherent to the therapy. Tacrolimus was the most commonly used drug, and no significant differences in adherence were found based on the type of immunosuppressant used. Adherent patients reported a better quality of life compared to non-adherent patients.

Conclusions: A significant proportion of liver transplant patients exhibit non-adherence to immunosuppressive therapy. Factors such as medication forgetfulness, time since transplantation, and the presence of chronic illnesses impact adherence. It is recommended to enhance patient-provider relationships, regularly assess adherence, and provide patient education to improve quality of life and minimize the risk of graft rejection.

Table. Comparison of sociodemographic and clinical variables according to immunosuppressive therapy adherence in liver transplant patients

	Adherent N = 17 (59%)	Non-Adherent N = 12 (41)	Total N = 29 (%)	P value
Sociodemographic information				
Age in years (median;IQR)	65 (58 – 67)	58.5 (45 – 66.5)	64 (54 – 67)	0.297
Male gender	10 (59)	6 (50)	16 (55)	0.716
Health insurance				
Public (Fonasa)	8 (47)	4 (33)	12 (41)	0.683
Private	9 (53)	8 (67)	17 (59)	
Education				
Media	8 (47)	5 (42)	13 (45)	0.537
Superior	9 (53)	7 (58)	16 (55)	
Monthly income allocated to medicines				
< 3%	7 (41)	4 (33)	11 (38)	0.364
3 – 10%	6 (35)	2 (17)	8 (28)	
> 10%	4 (24)	6 (50)	10 (34)	
Clinical information				
Nº of chronic diseases	1 (2 – 3)	0.5 (1 – 2)	1 (2 – 2)	0.047
Nº of medicines used daily				
≤ 5	8 (47)	6 (50)	14 (48)	1
> 5	9 (53)	6 (50)	15 (52)	
Time since transplantation in months (median;IQR)	23 (15 – 40)	80 (32 – 95)	37 (16 – 84)	0.033
Immunosuppressive therapy				
Glucocorticoids				
Prednisone	7 (41)	5 (42)	12 (41)	1
Calcineurin inhibitors	15 (88)	12 (100)	27 (93)	0.323
Cyclosporine	1 (6)	3 (25)	4 (14)	
Tacrolimus	14 (82)	9 (75)	23 (79)	
Antiproliferatives				
Mycophenolate mofetil	11 (65)	6 (50)	17 (56)	0.471
mTOR inhibitors	5 (29)	4 (33)	9 (31)	0.264
Everolimus	5 (29)	2 (17)	7 (24)	
Rapamycin	0 (0)	2 (17)	2 (7)	
Quality of Life				
Visual analogue scale (0 – 100) (median;IQR)	92 (50 – 100)	72.5 (70 – 80)	80 (70 – 95)	0.126

<https://doi.org/10.1016/j.aohep.2024.101703>

P-90 COMPARISON BETWEEN MILAN CRITERIA, FRENCH ALPHA-FETOPROTEIN MODEL, AND METROTICKET 2.0 FOR LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA.

Victor Nicolas Henriquez Auba¹,
Deycies Ivonne Gaete Letelier², Alvaro Urzúa¹,
Juan Pablo Roblero¹, Maximo Cattaneo¹, Lia Catalán¹,
Alexandre Sauré², Solange Adrian³, Daniela Simian¹,
Jaime Poniachik¹

¹ Gastroenterology Section, Department of Medicine, Clinical Hospital of the University of Chile, Santiago, Chile

² Surgery Section, Department of Medicine, Clinical Hospital of the University of Chile, Santiago, Chile

³ Faculty of Medicine and Science, San Sebastián University, Santiago, Chile

Conflict of interest: No

Introduction and Objectives: Milan criteria (MC) have been the standard for selecting candidates for liver transplantation (LT) for hepatocellular carcinoma (HCC). New strategies including alpha-feto-protein with tumor number and diameter, such as the French alpha-fetoprotein model (FM) and Metroticket2.0 (MT), improve prediction of recurrence and prognosis. **Objectives:**

To compare these three tools in terms of survival and tumor recurrence.

Patients / Materials and Methods: A cohort study of 79 LT patients with HCC (2006-2020). Patients were divided by MC: within (WMC) and outside (OMC). They were reclassified using FM into low risk (LRFM) and high risk (HRFM), and with Metroticket2.0: ≥75% 5 year survival (MT≥75) and <75% (MT<75). Clinical, histological characteristics and 5-year survival were analyzed.

Results and Discussion: Follow-up was 100% with a median of 65.7 months. 86% received therapy before LT. Median age was 62 years. Overall survival (OS) was 57%, and 7 (9%) patients had recurrence at an average of 10.2 months post-transplant. (range: (5.7-14.8);(2.1 - 38.9)). All recurrences resulted in death. In the WMC cohort (n=67), OS was 66.5 months, with 4 (6%) recurrences. In the OMC cohort (n=12), OS was 58.3 months, with 3 (25%) recurrences. For FM, LRFM patients (n=70) had an OS of 66.2 months, with 4 (6%) recurrences, while HRFM (n=9) had an OS of 41.8 months, with 3 (33%) recurrences. With MT, MT≥75 (n=70) had an OS of 66.9 months, with 4 (6%) recurrences, and MT<75 (n=9) had an OS of 41.8 months, with 3 (33%) recurrences.

Conclusions: LT in HCC has had a 5-year OS above 70% and a recurrence rate of 8%. There is a significant difference in 5-year survival and recurrence for OMC patients, and also with HRFM and MT<75 criteria.

<https://doi.org/10.1016/j.aohep.2024.101704>

P-91 NORMALIZATION OF ALKALINE PHOSPHATASE COMPARED TO CONVENTIONAL RESPONSE CRITERIA LEADS TO LOWER LIVER RELATED EVENTS AND MORTALITY IN PATIENTS LIVING WITH PRIMARY BILIARY CHOLANGITIS, TREATED WITH UDCA: A RETROSPECTIVE, PROPENSITY SCORED-MATCHED, COHORT STUDY

LUIS ALEJANDRO ROSALES RENTERIA¹,
José David Prieto Nava¹,
Giovanni Francisco Pérez Roa¹,
María Sarai González Huezó¹

¹ CENTRO MÉDICO ISSEMYM TOLUCA, Toluca, México

Conflict of interest: No

Introduction and Objectives: Primary biliary cholangitis (PBC) is a chronic, progressive, autoimmune liver disease characterized by the destruction of the small bile ducts within the liver. Ursodeoxycholic acid (UDCA) is the first-line treatment for PBC, shown to improve liver biochemistry and delay disease progression. All biochemical criteria for response recommend a threshold of alkaline phosphatase (ALP) that is higher than the ULN, because those scores have shown a lower disease progression, liver related events and overall mortality. The impact of achieving normalization of ALP, compared to conventional biochemical scores is unknown, but it's relevance, particularly in countries without universal access to liver transplantation could be significant.

Patients / Materials and Methods: This is a single center, retrospective, propensity score-matched cohort study, which included all patients with PBC and chronic liver disease, confirmed by liver biopsy that were followed by the hepatology clinic from January 1st, 2015 to March 1st 2024 under treatment with UDCA. All demographic, clinical and biochemical characteristics were obtained. A biochemical response was defined according to the Toronto criterion, with an ALP <1.67 x ULN after 2 years of UDCA therapy. Patients were subdivided into two groups, either by fulfilling these criteria or by achieving normalization of ALP <120 IU/L. The primary outcome was mortality due to a liver related event (LRE) a composite that included variceal hemorrhage (VH), spontaneous bacterial peritonitis (SBP), hepatic encephalopathy (HE), ascites, acute kidney injury (AKI), hepatorenal syndrome-AKI (HRS-AKI), and ACLF. The secondary outcomes were development of each independent variable of the definition of LRE.

Results and Discussion: Out of a total pool of 132 patients, 32 fulfilled conventional Toronto criteria without achieving normalization of ALP, and 30 had a ALP level below 120 IU/L. The predominant gender was female in both groups (95% and 96%) with a median of 57 years for both groups. The prevalence of systemic autoimmune disease was similar between both groups, (55 and 57%, respectively). Mortality due to LRE in the Toronto criteria group was 14/32 (43%), compared to 4/30 (13%) in the normalization group, a difference which was statistically significant (OR 5.05, 95% CI [1.429, 17.882], $p=0.005$). The development of HE (OR 5.47, 95% CI [1.075, 27.916], $p=0.02$) and VH (OR 4.71, 95% CI [1.165, 19.083], $p=0.01$), was greater in the Toronto criteria group, compared to the normalization group. These variables remained statistically significant after multivariate regression analysis (adjusted for age, gender and autoimmune systemic diseases).

No statistically significant differences were found for AKI, HRS-AKI, ACLF, ascites or SBP.

Conclusions: Among patients with PBC that receive initial therapy with UDCA, a normalization of ALP after two years, compared to conventional biochemical response criteria (Toronto criteria), leads to lower liver related mortality and development of VH and EH. More prospective studies are needed.




Figure 1. Mortality during follow up among patients with PBC that fulfilled Toronto criteria vs those that achieved a normal ALP. Mortality due to LRE in the Toronto criteria group was 14/32 (43%), compared to 4/30 (13%) in the normalization group, a difference which was statistically significant (OR 5.05, 95% CI [1.429, 17.882], $p=0.005$.)

P-92 CAN HONEY AND APICULTURAL DERIVATIVES HELP IN FATTY LIVER DISEASE?

Liena Martina Bravo Urquiza¹,
Marcelo Andia Kohnenkamp¹, Raquel Bridi²,
Juan Esteban Oyarzun Isamitt¹

¹ Biomedical Imaging Center, School of Medicine, Pontificia Universidad Católica de Chile, ANID-Millennium Institute for Intelligent Healthcare Engineering—iHEALTH, Santiago 7820436, Chile, Santiago de Chile, Chile

² Department of Pharmacological and Toxicological Chemistry, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380000, Chile, Santiago de Chile, Chile

Conflict of interest: No

Introduction and Objectives: The increase in caloric intake has led to an obesity epidemic both in Chile and worldwide. This trend has contributed to a rise in the prevalence of metabolic diseases, such as insulin resistance, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD). NAFLD affects approximately 25% of the global population and can progress to severe stages such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Currently, there is no formal protocol for the pharmacological treatment of NAFLD, making prevention and reversal crucial for improving quality of life and reducing public health costs. Honey and bee pollen, rich in antioxidants and known for their therapeutic properties, could offer a non-pharmaceutic alternative to manage this condition. **Objective:** This study aims to evaluate Chilean endemic honeys and bee pollens from Ulmo and Quillay, to determine their hepatoprotective effect in an in vitro cellular model.

Patients / Materials and Methods: For the cell assays, the HUH7 cell line was used. The compound AAPH (2,2'-azobis(2-amidinopropane) dihydrochloride) was employed as a peroxy radical generator to induce cellular damage. The hepatoprotective effect was evaluated by inducing cellular damage with AAPH (0.2 mM for 24 hours), followed by the addition of phenolic extracts from honeys or bee pollens at various concentrations. To isolate the effect of glucose, present in the honeys, artificial honey, created from a combination of different sugars, was used. Cell viability was determined using the Alamar Blue assay after 24 hours of incubation with the different treatments.

Results and Discussion: Hepatoprotective results were obtained by evaluating cell viability in the presence of Ulmo honey, Quillay honey, and bee pollen. Treatment of cells with AAPH resulted in cellular damage, significantly decreasing cell viability. However, the addition of Ulmo honey, Quillay honey, and bee pollen in co-treatment with AAPH reversed this effect, significantly increasing cell viability. These findings indicate a hepatoprotective effect of Ulmo and Quillay honeys, as well as bee pollen on cell viability compromised by AAPH. The presence of bioactive compounds, such as antioxidants and flavonoids, in these apicultural derivatives may explain their ability to protect liver cells from AAPH-induced oxidative damage.

Conclusions: In conclusion, Ulmo and Quillay honeys, as well as bee pollen, demonstrated to be effective hepatoprotective agents, suggesting their therapeutic potential in protecting liver health.

<https://doi.org/10.1016/j.aohep.2024.101706>

<https://doi.org/10.1016/j.aohep.2024.101705>